Nephrotoxicity and drug interaction of vancomycin (1)

Folia Pharmacologica Japonica

Volumn 107, Issue 2, 1996, Pages 53-66

  Toyoguchi, Teiko ^c   Nakagawa, Yoshito ^a   Watanabe, Hiroshi ^b  

^a YAMAGATA UNIVERSITY HOSPITAL   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN; IMIPENEM; VANCOMYCIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG POTENTIATION; DRUG TRANSPORT; DRUG UPTAKE; GRAM POSITIVE BACTERIUM; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; NONHUMAN; RABBIT; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION;

ANIMALS; ANTI-BACTERIAL AGENTS; CILASTATIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; IMIPENEM; KIDNEY; MALE; PROTEASE INHIBITORS; RABBITS; THIENAMYCINS; VANCOMYCIN;

EID: 0030071504     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.107.53     Document Type: Article

References (36)

1. Chemotherapy 40, 86-101 (1992)
2. Appel GB, Given DB, Levine LR and Cooper GL: Vancomycin and the kidney. Am J Kidney Dis 8 (2), 75-80 (1986)
3. Matzke GR, Zhanel GG and Guay DRP: Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 11, 257-282 (1986)
4. Rybak MJ, Albrecht LM, Boike SC and Chandrasekar PH: Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 25, 679-687 (1990)
5. Farber BF and Moellering RC: Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 23, 138-141 (1983)
6. Chemotherapy 40, 581-591 (1992)
7. Houghton DC, Wood C, Kohlhepp S, Bennett WM and Gilbert DN: Autoradiographic studies of renal vancomycin distribution with and without concomitant tobramycin administration. Clin Res 34, 52 (1986)
8. Fauconneau B, Lemos ED, Pariat C, Bouquet S, Courtois P and Piriou A: Chrononephrotoxicity in rat of a vancomycin and gentamicin combination. Pharmacol Toxicol 71, 31-36 (1992)
9. Wood CA, Kohlhepp SJ, Kohnen PW, Houghton DC and Gilbert DN: Vancomycin enhancement of experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother 30, 20-24 (1986)
10. Wold JS and Turnipseed SA: Toxicology of vancomycin in laboratory animals. Rev Infect Dis 3, S224-S229 (1981)
11. Chemotherapy 33(S-4), 1-13 (1985)
12. Chemotherapy 33(S-4), 54-73 (1985)
13. Chemotherapy 33(S-4), 217-226 (1985)
14. Chemotherapy 33(S-4), 329-356 (1985)
15. Cross RJ and Taggart JV: Renal tubular transport: Accumulation of p-aminohippurate by rabbit kidney slices. Am J Physiol 161, 181-190 (1950)
16. Chemotherapy 40(8), 1018-1031 (1992)
17. Hori R, Ishikawa Y, Takano M, Okano T, Kitazawa S and Inui K: The interaction of cephalosporin antibiotics with renal cortex of rats: Accumulation to cortical slices and binding to purified plasma membranes. Biochem Pharmacol 31, 2267-2272 (1982)
18. Marre R, Schulz E, Anders T and Sack K: Renal tolerance and pharmacokinetics of vancomycin in rats. J Antimicrob Chemother 14, 253-260 (1984)
19. Aronoff GR, Sloan RS, Dinwiddie CB, Glant MD, Fineberg NS and Luft FC: Effects of vancomycin on renal function in rats. Antimicrob Agents Chemother 19, 306-308 (1981)
20. Kropp H, Kahan FM, MacDonald JS and Birnbaum J: Imipenem-cilastatin. In Beta-Lactam Antibiotics for Clinical Use, Edited by Queener SF, Webber JA and Queener SW, pp471-526, Marcel Dekker, New York and Basel (1986)
21. Nivoche Y, Contrepois A, Cremieux AC and Carbon C: Vancomycin in rabbits: Pharmacokinetics, extravascular diffusion, renal excretion and interactions with furosemide. J Pharmacol Exp Ther 222, 237-240 (1982)
22. Moellering RC, Krogstad DJ and Greenblatt DJ: Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. Rev Infect Dis 3, S230-S235 (1981)
23. Nielsen HE, Hansen HE, Korsager B and Skov PE: Renal excretion of vancomycin in kidney disease. Acta Med Scand 197, 261-264 (1975)
24. Golper TA, Noonan HM, Elzinga L, Gilbert D, Brummett R, Anderson JL and Benett WM: Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther 43, 565-570 (1988)
25. Albrecht LM, Rybak MJ, Warbasse LH and Edwards DJ: Vancomycin protein binding in patients with infections caused by Staphylococcus Aureus. DICP Ann Pharmacother 25, 713-715 (1991)
26. Cutler NR, Narang PK, Lesko LJ, Ninos M and Power M: Vancomycin disposition: The importance of age. Clin Pharmacol Ther 36(6), 803-810 (1984)
27. Chemotherapy 40(2), 210-224 (1992)
28. Shin WG, Lee MG, Lee MH and Kim ND: Factors influencing the protein binding of vancomycin. Biopharm Drug Dispos 12, 637-646 (1991)
29. Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB and Riff LJ: Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother, 32, 848-852 (1988)
30. Sokol PP: Mechanism of vancomycin transport in the kidney: Studies in rabbit renal brush border and basolateral membrane vesicles. J Pharmacol Exp Ther 259, 1283-1287 (1991)
31. Chemotherapy 42(6), 699-706 (1994)
32. Hayashi T, Watanabe Y, Kumano K, Kitayama R, Yasuda T, Saikawa I, Katahira J, Kumada T and Shimizu K: Protective effect of piperacillin against nephrotoxicity of cephaloridine and gentamicin in animals. Antimicrob Agents Chemother 32, 912-918 (1988)